SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE, Feller A 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med 323:15621563.
  • 2
    Kann P, Piepkorn B, Schehler B, Lotz J, Prellwitz W, Beyer J 1996 Growth hormone substitution in growth hormone-deficient adults: Effects on collagen type I synthesis and skin thickness. Exp Clin Endocrinol (Oxf) Diabetes 104:327333.
  • 3
    Clanget C, Seck T, Hinke V, Wuster C, Ziegler R, Pfeilschifter J 2001 Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 55:9399.
  • 4
    Wuester C, Abs R, Bengtsson B, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P 2001 The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16:398405.
  • 5
    Drake WM, Rodriguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP 2001 The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: A 5-year study. Clin Endocrinol (Oxf) 54:525532.
  • 6
    Wüster C 1995 Growth hormone, insulin-like growth factors and bone metabolism. Endocrinol Metab 2:312.
  • 7
    Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563566.
  • 8
    Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620625.
  • 9
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth-factor-i and risk of breast-cancer. Lancet 351:13931396.
  • 10
    Cohen P, Yang HC, Maronport R 2002 Interactions between caloric intake and the GH-IGF-IGFBP axis in prostate carcinogenesis. Growth Hormone IGF Res 12:262.
  • 11
    Hennessey JV, Chromiak JA, DellaVentura S, Reinert SE, Puhl J, Kiel DP, Rosen CJ, Vandenburgh H, MacLean DB 2001 Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 49:852858.
  • 12
    Landin Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson B-Å 2003 Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized, placebo-controlled trial. J Bone Miner Res 18:393405.
  • 13
    Zhang M, Xuan S, Bouxsein ML, Stechow D, Akeno N, Faugere M, Maulluche H, Zhao G, Rosen CJ, Efstriatiadis A, Clemens TL 2002 Osteoblast specific knockout of the IGF receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:4400544012.
  • 14
    Andreassen TT, Oxlund H 2000 The influence of combined parathyroid hormone and growth hormone treatment on cortical bone in aged ovariectomized rats. J Bone Miner Res 15:22662275.
  • 15
    Biller BMK, Sesmilo G, Baum HBA, Hayden D, Schoenfeld D, Klibanski A 2000 Withdrawal of long-term physiological growth hormone (GH) administration: Differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 85:970976.
  • 16
    Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84:12141219.
  • 17
    Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ 2002 IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:42734279.
  • 18
    Aloia JF, Zanzi I, Vaswani A, Ellis K, Cohn SH 1977 Combination therapy for osteoporosis. Metab Clin Exper 26:787792.
  • 19
    Erdtsieck RJ, Pols HAP, Valk NK, van Ouwerkerk BM, Lamberts SWJ, Mulder P, Birkenhager JC 1995 Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: A placebo controlled trial. Clin Endocrinol (Oxf) 43:557565.
  • 20
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 21
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:21292134.
  • 22
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ 2001 Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86:11161125.
  • 23
    Wüster C, Härle U, Rehn U, Müller C, Knauf K, Köppler D, Schwabe C, Ziegler R 1998 Benefits of grouch hormone treatment on bone metabolism, bone density, and bone strength in growth hormone deficiency and osteoporosis. Growth Horm IGF Res 8:8794.